MET as a target for treatment of chest tumours

Por Cipriani, Nicole A., Abidoye, Oyewale O., Vokes, Everett E., Salgia, Ravi
Publicado em 2008

Cyclooxygenase-2 (COX-2) As a Predictive Marker for the Use of COX-2 Inhibitors in Advanced Non–Small-Cell Lung Cancer

Por Edelman, Martin J., Hodgson, Lydia, Wang, Xiaofei, Kratzke, Robert A., Vokes, Everett E.
Publicado em 2012

Crizotinib (PF02341066) as a ALK /MET inhibitor— Special Emphasis as a Therapeutic Drug Against Lung Cancer

Por Nwizu, Tobenna, Kanteti, Rajani, Kawada, Ichiro, Rolle, Cleo, Vokes, Everett E., Salgia, Ravi
Publicado no Drugs Future (2011)

Factors Associated with Clinical Benefit from Epidermal Growth Factor Receptor Inhibitors in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck

Por Wyssam Cohen, Ezra Eddy, Halpern, Anna B., Kasza, Kristen, Kocherginsky, Masha, Williams, Rosalyn, Vokes, Everett E.
Publicado em 2009

Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103

Por Rudin, Charles M., Salgia, Ravi, Wang, Xiaofei, Hodgson, Lydia D., Masters, Gregory A., Green, Mark, Vokes, Everett E.
Publicado em 2008

Efficacy of the Multi-Kinase Inhibitor Enzastaurin is Dependent on Cellular Signaling Context

Por Kuo, Wen-Liang, Liu, Jing, Mauceri, Helena, Vokes, Everett E, Weichselbaum, Ralph, Rosner, Marsha Rich, Cohen, Ezra Eddy Wyssam
Publicado em 2010

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Ca...

Por Govindan, Ramaswamy, Bogart, Jeffrey, Stinchcombe, Thomas, Wang, Xiaofei, Hodgson, Lydia, Kratzke, Robert, Garst, Jennifer, Brotherton, Timothy, Vokes, Everett E.
Publicado em 2011

Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report

Por Dudek, Arkadiusz Z., Pang, Herbert, Kratzke, Robert A., Otterson, Gregory A., Hodgson, Lydia, Vokes, Everett E., Kindler, Hedy L.
Publicado em 2012

Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy

Por Maggiore, Ronald J., Curran, Emily K., Witt, Mary Ellyn, Haraf, Daniel J., Vokes, Everett E., Cohen, Ezra E.W.
Publicado no J Geriatr Oncol (2013)

The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium

Por Nimeiri, Halla S., Singh, Deepti A., Kasza, Kristen, Taber, David A., Ansari, Rafat H., Vokes, Everett E., Kindler, Hedy L.
Publicado no Invest New Drugs (2009)

Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B trial 9430

Por Stinchcombe, Thomas E., Mauer, Ann M., Hodgson, Lydia D., Herndon, James E., Lynch, Thomas J., Green, Mark. R., Vokes, Everett E.
Publicado em 2008

A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Por Miller, Antonius A., Pang, Herbert, Hodgson, Lydia, Ramnath, Nithya, Otterson, Gregory A., Kelley, Michael J., Kratzke, Robert A., Vokes, Everett E.
Publicado em 2010

Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study

Por Ready, Neal E., Dudek, Arkadiusz Z., Pang, Herbert H., Hodgson, Lydia D., Graziano, Stephen L., Green, Mark R., Vokes, Everett E.
Publicado em 2011

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer

Por Kanteti, Rajani, El-Hashani, Essam, Dhanasingh, Immanuel, Tretiakova, Maria, Husain, Aliya N, Sharma, Sherven, Sharma, Jay, Vokes, Everett E, Salgia, Ravi
Publicado em 2014

Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy d...

Por Salama, Joseph K., Pang, Herbert, Bogart, Jeffery A., Blackstock, A. William, Urbanic, James J., Hodgson, Lydia, Crawford, Jeffery, Vokes, Everett E.
Publicado em 2013

Integrated Genomic Analysis Suggests MLL3 is a Novel Candidate Susceptibility Gene for Familial Nasopharyngeal Carcinoma

Por Sasaki, Mark M, Skol, Andrew D, Bao, Riyue, Rhodes, Lindsay V, Chambers, Rachelle, Vokes, Everett E, Cohen, Ezra EW, Onel, Kenan
Publicado no Cancer Epidemiol Biomarkers Prev (2015)

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

Por Jahan, Thierry, Gu, Lin, Kratzke, Robert, Dudek, Arkadiusz, Otterson, Gregory A., Wang, Xiaofei, Green, Mark, Vokes, Everett E., Lee Kindler, Hedy
Publicado no Lung Cancer (2011)

Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097)

Por Ramalingam, Suresh S., Belani, Chandra P., Mack, Philip C., Vokes, Everett E., Longmate, Jeffrey, Govindan, Ramaswamy, Koczywas, Marianna, Ivy, S. Percy, Gandara, David R.
Publicado em 2010

Protein kinase C beta (PKCβ) in malignant pleural mesothelioma

Por Faoro, Leonardo, Loganathan, Sivakumar, Westerhoff, Maria, Modi, Rahul, Husain, Aliya N., Tretiakova, Maria, Seiwert, Tanguy, Kindler, Hedy L., Vokes, Everett E., Salgia, Ravi
Publicado em 2008

Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited stage small cell lung cancer: CALGB 30206

Por Kelley, Michael J., Bogart, Jeffrey A., Hodgson, Lydia. D., Ansari, Rafat. H., Atkins, James N., Pang, Herbert, Green, Mark R., Vokes, Everett E.
Publicado em 2013